From telemedicine to remote
site visits: the post-COVID
face of pharma research and

The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more flexible response to some long-standing issues with the clinical trials process. Read our article, in collaboration with pharmaphorum, to learn more.